These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 1909701)

  • 1. Suppression of the pituitary-gonadal axis in children with central precocious puberty: effects on growth, growth hormone, insulin-like growth factor-I, and prolactin secretion.
    Sklar CA; Rothenberg S; Blumberg D; Oberfield SE; Levine LS; David R
    J Clin Endocrinol Metab; 1991 Oct; 73(4):734-8. PubMed ID: 1909701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in growth and serum growth hormone and plasma somatomedin-C levels during suppression of gonadal sex steroid secretion in girls with central precocious puberty.
    Mansfield MJ; Rudlin CR; Crigler JF; Karol KA; Crawford JD; Boepple PA; Crowley WF
    J Clin Endocrinol Metab; 1988 Jan; 66(1):3-9. PubMed ID: 2961786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
    J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between luteinizing hormone and estradiol secretion in female precocious puberty: evaluation by sensitive gonadotropin assays and the leuprolide stimulation test.
    Garibaldi LR; Aceto T; Weber C; Pang S
    J Clin Endocrinol Metab; 1993 Apr; 76(4):851-6. PubMed ID: 8473395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of sex steroids by a gonadotrophin-releasing hormone agonist increases serum growth hormone-binding protein activity in girls with central idiopathic precocious puberty.
    Kobayashi Y; Murata A; Yasuda T; Minagawa M; Wataki K; Ohnishi H; Niimi H
    Clin Endocrinol (Oxf); 1994 Mar; 40(3):351-5. PubMed ID: 8187298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of long-acting analog of luteinizing hormone-releasing hormone on growth hormone secretory dynamics in children with precocious puberty.
    DiMartino-Nardi J; Wu R; Fishman K; Saenger P
    J Clin Endocrinol Metab; 1991 Oct; 73(4):902-6. PubMed ID: 1909708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of luteinizing hormone-releasing hormone analog for central precocious puberty on growth hormone (GH) and GH-binding protein.
    DiMartino-Nardi J; Wu R; Varner R; Wong WL; Saenger P
    J Clin Endocrinol Metab; 1994 Mar; 78(3):664-8. PubMed ID: 8126139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.
    Boepple PA; Mansfield MJ; Wierman ME; Rudlin CR; Bode HH; Crigler JF; Crawford JD; Crowley WF
    Endocr Rev; 1986 Feb; 7(1):24-33. PubMed ID: 2937629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pubertal growth spurt in eight patients with true precocious puberty and growth hormone deficiency: evidence for a direct role of sex steroids.
    Attie KM; Ramirez NR; Conte FA; Kaplan SL; Grumbach MM
    J Clin Endocrinol Metab; 1990 Oct; 71(4):975-83. PubMed ID: 2401720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-related alterations in pituitary and testicular functions in long-lived growth hormone receptor gene-disrupted mice.
    Chandrashekar V; Dawson CR; Martin ER; Rocha JS; Bartke A; Kopchick JJ
    Endocrinology; 2007 Dec; 148(12):6019-25. PubMed ID: 17872367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatomedin-C in normal puberty and in true precocious puberty before and after treatment with a potent luteinizing hormone-releasing hormone agonist.
    Harris DA; Van Vliet G; Egli CA; Grumbach MM; Kaplan SL; Styne DM; Vainsel M
    J Clin Endocrinol Metab; 1985 Jul; 61(1):152-9. PubMed ID: 3889035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low growth hormone levels are related to increased body mass index and do not reflect impaired growth in luteinizing hormone-releasing hormone agonist-treated children with precocious puberty.
    Kamp GA; Manasco PK; Barnes KM; Jones J; Rose SR; Hill SC; Cutler GB
    J Clin Endocrinol Metab; 1991 Feb; 72(2):301-7. PubMed ID: 1991801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irreversible increase of serum IGF-1 and IGFBP-3 levels in GnRH-dependent precocious puberty of different etiologies: implications for the onset of puberty.
    Belgorosky A; Rivarola MA
    Horm Res; 1998; 49(5):226-32. PubMed ID: 9568807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-year results of treatment with depot leuprolide acetate for central precocious puberty.
    Neely EK; Hintz RL; Parker B; Bachrach LK; Cohen P; Olney R; Wilson DM
    J Pediatr; 1992 Oct; 121(4):634-40. PubMed ID: 1403402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor agonist: effect on growth, sexual maturation, pelvic sonography, and the hypothalamic-pituitary-gonadal axis.
    Styne DM; Harris DA; Egli CA; Conte FA; Kaplan SL; Rivier J; Vale W; Grumbach MM
    J Clin Endocrinol Metab; 1985 Jul; 61(1):142-51. PubMed ID: 3923027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GnRH agonist stimulation of the pituitary-gonadal axis in children: age and sex differences in circulating inhibin-B and activin-A.
    Elsholz DD; Padmanabhan V; Rosenfield RL; Olton PR; Phillips DJ; Foster CM
    Hum Reprod; 2004 Dec; 19(12):2748-58. PubMed ID: 15513981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty.
    Feuillan PP; Jones JV; Barnes K; Oerter-Klein K; Cutler GB
    J Clin Endocrinol Metab; 1999 Jan; 84(1):44-9. PubMed ID: 9920060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 levels in children with precocious puberty treated with gonadotropin-releasing hormone analog without or in combination with cyproterone acetate.
    Verrotti A; Ferrari M; Sabatino G; Morgese G; Chiarelli F
    Gynecol Endocrinol; 1997 Aug; 11(4):243-50. PubMed ID: 9272420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. Effects on somatic growth and skeletal maturation.
    Mansfield MJ; Beardsworth DE; Loughlin JS; Crawford JD; Bode HH; Rivier J; Vale W; Kushner DC; Crigler JF; Crowley WF
    N Engl J Med; 1983 Nov; 309(21):1286-90. PubMed ID: 6415479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overnight levels of luteinizing hormone, follicle-stimulating hormone and growth hormone before and during gonadotropin-releasing hormone analogue treatment in short boys born small for gestational age.
    van der Kaay DC; de Jong FH; Rose SR; Odink RJ; Bakker-van Waarde WM; Sulkers EJ; Hokken-Koelega AC
    Horm Res; 2009; 71(5):260-7. PubMed ID: 19339790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.